Cumulative incidence curves of recovery by group. by Jae-Heung Cho (798319)

Subjects:

S1 Data - by Francois Kiemde (5369657)

“…Cortisol and prolactin levels decreased after delivery, though the level of prolactin was still higher than that at enrolment. …”

Characteristic of study population. by Francois Kiemde (5369657)

“…Cortisol and prolactin levels decreased after delivery, though the level of prolactin was still higher than that at enrolment. …”

Assessing Bivalves as Biomonitors of Per- and Polyfluoroalkyl Substances in Coastal Environments by Shannon E. Jones (17558652)

“…Overall, the summed PFAS concentration in the bivalves closely mirrors that in water. We observed higher bioaccumulation factors for some perfluoroalkyl sulfonamides and branched PFAS isomers than for terminal PFAS of equivalent chain length. …”

<i>Leptospira interrogans</i> from Okinawa induces epithelial barrier disruption with different kinetics. by Tetsuya Kakita (4922584)

iKIR score decreases protection associated with protective class II genotypes in T1D. by Laura Mora-Bitria (20477525)

Variation of the most appropriate p value significance threshold with different ratios of the standard deviations and sample sizes. by Farrokh Habibzadeh (12256529)

ASFV-ΔI7L induces higher immune responses than does ASFV-WT in pigs. by Meilin Li (1832905)

In individuals affected by PCA, there is a significant downregulation of genes associated with the cholesterol biosynthetic pathway. by Leemon Nikhila (22250736)

A prepubertal CD decreases plasma leptin and cholesterol concentrations in adulthood despite a chronic HFD in Sprague-Dawley male rats. by Ana Aguilar-Lozano (20614619)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects: